|
|
Other links at Articles > Business of Medicine |
| 2. |
Bivalirudin "Nonapprovable" for ACUITY Indication
|
|
|
The US FDA has issued a "not-approvable" letter to the Medicines Company for an additional dosing regimen of the drug covering upstream treatment of ACS initiated in the emergency department, based on the ACUITY trial. Heartwire
|
|
|